Not throwing away my shot. I am sorry folks...nothing of

New Post Public Reply Private Reply Replies (12) Message Board
jconst345 Goosebumps #83959
1,305
Not throwing away my shot.

I am sorry folks...nothing of substance to post here...except for how I felt about yesterday's call.

It was BY FAR the best call I've personally heard them conduct (in the past ~10 months).

They sounded the most optimistic, the most buttoned up & professional, the least speculative, and talked about the most optionality going forward. Btw, loved Arian (lawyer) setting the record straight on multiple questions, here here!

-EUA on the table, here & in multiple countries
-CD16 - Slam dunk trial will take care of the above if not granted sooner
-CD17 - could be an added subgroup for EUA, but will also pay dividends re: IV knowledge gained for both Covid & all future trials
-HIV receptor occupancy concerns addressed, underway, will be resolved, BLA filed summer, PDUFA at end of year/early 2022
-FDA is friend, not fiend (Mahboob & Nader's comments were both adamant & very reassuring to me)
-Pharma trial partnerships (no no no, please, let me pay the check) on the table
-Samsung revving their engines on our behalf w/ millions of vials of potential as needed
-100% receptor occupancy...wow
-World is aware of CYDY - as far south as Brazil, as far east as Hungary in Europe & Philippines in APAC
-Nader the bulldog has stamp of approval from board
-"Real" lawsuits are behind us, the others are fake news
-Long haulers anecdotes seem positive
-Cancer anecdotes seem positive
-And we all know anecdotes don't come off life support
-Cancer + all future trials/indications are so mind boggling it's hard to wrap my tiny brain around the potential...they are, in some cases, providing clemency for a death sentence. Imagine you are told you will die in 4-6 months, yet you are alive 12 months+, think about that... you don't get to play this game twice... what's that worth to you?

I absolutely love market inefficiencies, LOVE IT. I can buy 2-3x as much for the same $1 here as I could at $4.50 or $6.75. Literally doubling or tripling my eventual payout. Never thought I'd have the chance to add down at these prices, never. I'll take it as a win for me personally.

Kelly:
-'tumor microenvironment is loaded with ccr5'
-'future of Cytodyn is oncology'
-'Covid critical pales in comparison to opportunity in long haulers, long haulers absolutely pales in comparison to oncology'

How Mulholland doesn't jump off a cliff after answering yet another uplist question is beyond me. Torturous.

A few quick Buffett quotes, because he's the oracle for good reason:
"Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble."

"Risk comes from not knowing what you're doing."

"You are neither right nor wrong because the crowd disagrees with you. You are right because your data and reasoning are right."

"Buy into a company because you want to own it, not because you want the stock to go up."
-->I actually feel unbelievably proud AND comfortable sitting on these shares. I am literally entrusting this team to my hard earned cash, I have no problem with that. This team are positive, focused, devoted, and sincere. I have no issue putting faith in them to do the right thing with my $$.

And my personal fav:
"The stock market is a device for transferring money from the impatient to the patient."

So, yes I'm CGiddy and have plenty of Goosebumps. I'll sit & meditate, as my techGURU has taught me, and say my "Ohm's" while waiting patiently for the long term story to play out. In the meantime I'll watch "If you believe in it, they will come" - BorelFields of Dreams. And to all the shorts out there, I'll soon misiu very much...as a HHIGambler, you gotta know when to fold em. Feeling smurphy about things as I can see Zaius on Mt. Olympus getting ready with his LLightning bolt, don't blink or you'll miss it. Float like a butterfly, calstang like a bee. You KenChowder down on that! Shout outs to all those I've missed, the good ones know who you are. ExCYDYng times ahead for Penicillin 2.0. Ali G signing off - Respert!

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DJI Puts 3D Conservation Tools to Work Across Segovia

Updated Category News Views 59

Stone monuments do not care about marketing slogans; they care whether somebody notices the crack before winter gets hold of it. That is why DJI’s World Heritage 3D Conservation Initiative in Segovia lands as more than a shiny drone-company ceremony. The company gathered winning 3D fly-through work from its first initiative, but the useful bit was the case for turning...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 143

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 16

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 70

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 114

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 47

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 122

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Africa’s Digital Ownership Debate Gets More Serious

Updated Category News Views 64

Ownership was the uncomfortable word hanging over Cape Town on day two of Africa Tech Festival 2026, and frankly it should make investors sit up. Africa’s digital economy has no shortage of big promises, shiny AI demos or overseas executives talking about opportunity. The harder question is who funds the pipes, owns the data, makes the rules and actually keeps the...

Continue Reading

Top 5 Most Recently Viewed Articles

FirstEnergy Reports Strong Q3 2024 Financial Outcomes

Updated Category News Views 232

Strong Third Quarter Earnings Performance FirstEnergy Corp. recently revealed impressive financial results for the third quarter of 2024, showcasing GAAP earnings from continuing operations at $419 million. This translates to earnings per share of $0.73, demonstrating slight retention from the previous year's earnings of $421 million, which were $0.74 per share on...

Continue Reading
Apple Delays Apple Intelligence in EU Over DMA Concerns

Updated Category Business Views 583

Apple Delays Launch of Apple Intelligence in EU Due to Regulatory Hurdles The European Union launch of Apple Intelligence AI product will be delayed, the company said. The "regulatory uncertainties" pertaining to the Digital Markets Act (DMA) of the EU are the cause of the delay. Apple voiced worries that the DMA might jeopardize the quality of their offerings. Keeping...

Continue Reading
AMVital Turmeric Soap Achieves Top Sales and Customer Satisfaction

Updated Category News Views 219

AMVital Turmeric Soap Surges in Popularity AMVital, a prominent name in turmeric skincare, has made waves in the beauty market. Their Turmeric Kojic Acid Soap Bar recently secured the top spot on Walmart Marketplace, outpacing competitors and earning substantial consumer trust. Exceptional Customer Feedback This innovative soap has amassed over 13,000 verified reviews...

Continue Reading
ChemoMetec Expands Its Portfolio with Ovizio Acquisition

Updated Category News Views 90

ChemoMetec Acquires Ovizio Imaging Systems SA ChemoMetec has taken an important step by submitting a binding tender offer for the complete acquisition of Belgian company Ovizio Imaging Systems SA. This decision comes after careful consideration and a thorough due diligence process. Details of the Acquisition The acquisition is set at a price of EUR 2,830,000. Exciting...

Continue Reading
Tether's Vision: Dirham-Pegged Stablecoin and More

Updated Category News Views 135

Tether's New Dirham-Pegged Stablecoin Initiative During a recent interview, Tether CEO Paolo Ardoino provided valuable insights about the company’s latest developments. One of the key announcements was the upcoming launch of a stablecoin pegged to the UAE's currency, the Dirham. The introduction of this stablecoin reflects Tether's commitment to adapting to the evolving...

Continue Reading